Table 1 Clinicopathologic characteristics of study population
Characteristics | All (n = 135) | Extended chemotherapy (n = 52) | Standard chemotherapy (n = 83) | P |
|---|---|---|---|---|
Age at initial diagnosis, years | 55.5 ± 10.1 | 55.0 ± 9.0 | 55.9 ± 10.7 | 0.624 |
Age at 1st recurrence, years | 57.4 ± 9.9 | 56.6 ± 9.1 | 57.9 ± 10.4 | 0.475 |
Primary site of disease | 0.314 | |||
Ovary | 123 (91.1) | 46 (88.5) | 77 (92.8) | |
Tube | 4 (3.0) | 1 (1.9) | 3 (3.6) | |
Peritoneum | 8 (5.9) | 5 (9.6) | 3 (3.6) | |
Histologic type | 0.344 | |||
Serous | 120 (88.9) | 46 (88.5) | 74 (89.2) | |
Endometrioid | 8 (5.9) | 3 (5.8) | 5 (6.0) | |
Mucinous | 1 (0.7) | 1 (1.9) | 0 | |
Clear cell | 3 (2.2) | 2 (3.8) | 1 (1.2) | |
Mixed | 3 (2.2) | 0 | 3 (3.6) | |
Grade | 0.136 | |||
1 | 4 (3.0) | 3 (5.8) | 1 (1.2) | |
2 | 7 (5.2) | 1 (1.9) | 6 (7.2) | |
3 | 124 (91.9) | 48 (92.3) | 76 (91.6) | |
FIGO stage | 0.496 | |||
I-II | 9 (6.7) | 5 (9.6) | 4 (4.8) | |
III | 88 (65.2) | 34 (65.4) | 54 (6.1) | |
IV | 38 (28.1) | 13 (25.0) | 25 (30.1) | |
Primary treatment strategy | 0.540 | |||
PDS | 100 (74.1) | 37 (71.2) | 63 (75.9) | |
NAC | 35 (25.9) | 15 (28.8) | 20 (24.1) | |
Results of initial debulking surgery | 0.041 | |||
Complete gross resection | 72 (53.3) | 22 (42.3) | 50 (60.2) | |
Residual tumor <1 cm | 36 (26.7) | 20 (38.5) | 16 (19.3) | |
Residual tumor ≥1 cm | 27 (20.0) | 10 (19.2) | 17 (20.5) | |
Platinum-free interval, months | ||||
Median (range) | 12.5 (6.0–87.9) | 11.0 (6.2–87.9) | 13.1 (6.0–84.5) | 0.018 |
6–12, partially platinum-sensitive | 61 (45.2) | 28 (53.8) | 33 (39.8) | 0.109 |
≥12, totally platinum-sensitive | 74 (54.8) | 24 (46.2) | 50 (60.2) | |
CA-125 at 1st recurrence, IU/mL | 0.152 | |||
Median (range) | 91.0 (7.9–6290.0) | 99.1 (12.0–6290.0) | 91.0 (7.9–1908.0) | |
Secondary debulking surgery | 0.003 | |||
No | 118 (87.4) | 51 (98.1) | 67 (80.7) | |
Yes | 17 (12.6) | 1 (1.9) | 16 (19.3) | |
Results of secondary debulking surgery | 0.279 | |||
Complete gross resection | 6 (4.4) | 0 | 6 (7.2) | |
Residual tumor <1 cm | 6 (4.4) | 0 | 6 (7.2) | |
Residual tumor ≥1 cm | 5 (3.7) | 1 (1.9) | 4 (4.8) | |
Residual tumor on CT after #6 | 0.232 | |||
≥0.5 cm and <1 cm | 65 (48.1) | 28 (53.8) | 37 (44.6) | |
≥1 cm and <2 cm | 56 (41.5) | 17 (32.7) | 39 (47.0) | |
≥2 cm | 14 (10.4) | 7 (13.5) | 7 (8.4) | |
CA-125 after #6, IU/mL | 0.122 | |||
Median (range) | 12.5 (1.1–445.0) | 14.0 (1.1–249.0) | 11.0 (1.1–445.0) | |
Maintenance therapy | ||||
No | 98 (72.6) | 46 (88.5) | 52 (62.7) | 0.001 |
Yes | 37 (27.4) | 6 (11.5) | 31 (37.3) | |
Bevacizumab | 29 (21.5) | 5 (9.6) | 24 (28.9) | >0.999 |
Olaparib | 8 (5.9) | 1 (1.9) | 7 (8.4) | |
Germline BRCA1/2 gene test | ||||
Not performed | 51 (37.8) | 23 (44.2) | 28 (33.7) | 0.221 |
Performed | 84 (62.2) | 29 (55.8) | 55 (66.3) | |
Wild-type | 58 (43.0) | 21 (40.4) | 37 (44.6) | 0.628 |
Mutation | 26 (19.3) | 8 (15.4) | 18 (21.7) | |